Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14269010 | 1.00 | TAS1R3 (0.40) | TAS1R3TAS1R1MMECYP3A4MAPK1 | |
| SCHEMBL13035554 | 1.00 | TAS1R3 (0.40) | TAS1R3TAS1R1MMECYP3A4MAPK1 | |
| SCHEMBL7990837 | 0.86 | CYP3A4 (0.43) | MMECYP3A4MAPK1CNR1CNR2 | |
| SCHEMBL4341862 | 0.82 | TAS1R3 (0.42) | TAS1R3TAS1R1MMECNR1ALDH1A1 | |
| SCHEMBL9572303 | 0.82 | SLC7A5 (0.47) | TAS1R3TAS1R1MMECYP3A4MAPK1 | |
| SCHEMBL19439391 | 0.82 | ANPEP (0.42) | TAS1R3TAS1R1MMECYP3A4MAPK1 | |
| SCHEMBL30952371 | 0.82 | USP2 (0.47) | TAS1R3TAS1R1MMECYP3A4MAPK1 | |
| SCHEMBL25839087 | 0.82 | CYP3A4 (0.36) | MMECYP3A4MAPK1CNR1CNR2 | |
| SCHEMBL25842102 | 0.82 | CYP3A4 (0.36) | MMECYP3A4MAPK1CNR1CNR2 | |
| SCHEMBL10079223 | 0.80 | MMP1 (0.40) | TAS1R3TAS1R1MMECYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4275759-A2 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | TAS1R3 2683/4885TAS1R1 1652/4885MME 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.